Abiraterone Acetate Tablet, Film Coated
Product Images NDC 51407-989

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Abiraterone Acetate (NDC 51407-989). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

51407-989-60lb.jpg (51407 989 60lb)

Label for Abiraterone Acetate tablets USP, 500 mg, film-coated oral tablets. The label shows the 60-tablet bottle size, marked Rx Only, and lists Golden State Medical Supply, Inc. as the labeler. It includes storage instructions, a barcode, lot, expiration, and serial number spaces, and patient dispensing information.*

FDA Label Image

Abiraterone Acetate Structural Formula (Image 03)

Chemical structure diagram of abiraterone acetate, showing the arrangement of carbon, hydrogen, oxygen, and nitrogen atoms in the molecule.*

FDA Label Image

Figure 1: Kaplan-meier Overall Survival Curves In Cou-aa-301 (intent-to-treat Analysis) (Image 04)

A survival curve chart showing percentage survival over time to death in months for two groups: one treated with Abiraterone acetate and one with placebo. The chart plots survival percentage on the vertical axis against time in months on the horizontal axis, with separate lines for Abiraterone acetate and placebo treatments. Numbers at risk for both groups are displayed below the time axis.*

FDA Label Image

Figure 2: Kaplan Meier Overall Survival Curves In Cou-aa-302 (Image 05)

A Kaplan-Meier survival curve chart comparing the percentage of subjects without death over time (months from randomization) between abiraterone acetate and placebo groups. The solid line represents abiraterone acetate, and the dashed line represents placebo, with subject counts at risk shown along the x-axis below the chart.*

FDA Label Image

Figure 3: Kaplan Meier Curves Of Radiographic Progression-free Survival In Cou-aa-302 (intent-to-treat Analysis) (Image 06)

A Kaplan-Meier survival curve comparing the percentage of subjects without radiographic progression or death over time (months from randomization) between placebo and abiraterone acetate groups. The y-axis represents the percentage of subjects without progression or death, and the x-axis shows months from randomization. The chart includes subject counts at various time points for both groups.*

FDA Label Image

Figure 4: Kaplan-meier Plot Of Overall Survival; Intent-to-treat-population In Latitude Updated Analysis (Image 07)

A line graph showing the percentage survival of subjects without death over a period of months from randomization. The graph compares two groups, one receiving Abiraterone acetate and the other a placebo, with survival percentage on the y-axis and months from randomization on the x-axis. Numbers of subjects at risk at various time points are displayed below the x-axis for both groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.